USA Cybersecurity: The FDA's RTA Threat. A Pure Global Medtech Brief.

Failed to add items

Sorry, we are unable to add the item because your shopping basket is already at capacity.

Add to cart failed.

Please try again later

Add to wishlist failed.

Please try again later

Remove from wishlist failed.

Please try again later

Follow podcast failed

Unfollow podcast failed

USA Cybersecurity: The FDA's RTA Threat. A Pure Global Medtech Brief.

Listen for free

View show details

About this listen

Last week, the FDA sent a clear message to the MedTech industry by halting a major device submission over cybersecurity flaws. This episode of MedTech Global Insights dissects the new reality of the FDA's "Refuse to Accept" policy and what it means for manufacturers. We go beyond the headlines to reveal the specific requirements that are now non-negotiable for market approval in the United States. This is a fundamental shift in regulatory enforcement, where a weak cybersecurity plan can completely derail your product launch. We explore how this impacts everything from initial device design to post-market responsibilities, turning cybersecurity from a technical checkbox into a critical business strategy. Imagine your multi-million dollar device submission being stopped, not for clinical data issues, but because your Software Bill of Materials was incomplete. We explore this scenario that is every MedTech leader's new nightmare. Key questions answered in this episode: 1. What does an FDA "Refuse to Accept" notice for cybersecurity truly mean for a product's launch timeline? 2. Is your Secure Product Development Framework (SPDF) robust enough to pass the new FDA scrutiny? 3. Why is a Software Bill of Materials (SBOM) now a non-negotiable part of your submission? 4. How can you demonstrate 'reasonable assurance' of device security to regulators? 5. What are the three most common cybersecurity gaps that trigger an RTA notice? 6. How do the new rules affect legacy devices already on the market? 7. What post-market vulnerability management strategies does the FDA expect to see? For more information, contact us at info@pureglobal.com or visit https://pureglobal.com/. For FREE AI tools and a comprehensive medical device database, visit https://pureglobal.ai/.

No reviews yet